New Strategic Alliance for Cancer Research
The START Center for Cancer Research, known for its pioneering work in early-phase cancer clinical trials, has announced a promising partnership with Fundación Rioja Salud. This collaboration aims to significantly enhance access to innovative cancer treatments through the establishment of a new clinical trial facility in La Rioja, Spain.
Formation of an Early Phase Unit
By launching this additional early-phase unit, START continues to expand its comprehensive network of clinical trial sites, which already includes eight locations worldwide and a dedicated team of 25 Principal Investigators. The initiative will ensure that patients in the La Rioja area have access to the latest cancer treatment options.
Enhanced Options for Patients
The new site will be strategically located within San Pedro University Hospital, a facility that accommodates approximately 1,800 new cancer patients annually. This positioning is vital for patients living in northern provinces, including Aragón, País Vasco, Navarra, Castilla y León, Cantabria, and Asturias, where access to major oncology centers like those in Madrid and Barcelona can be challenging.
Community Impact and Benefits
Juan Carlos Oliva Peréz, CEO of Rioja Salud, expressed enthusiasm about joining forces with START. "This partnership enables us to offer our community access to the forefront of cancer research and treatment options that were previously unavailable in our region," he stated. The collaboration reflects a shared commitment to bring cutting-edge care closer to patients in need.
Expanding the Network for Cancer Research
This partnership not only signifies a major step for START but also aligns with its broader mission of enhancing community health through research. Nick Slack, Chairman and CEO of START, emphasized that expanding into La Rioja is pivotal for reaching more patients with the latest advancements in cancer treatment and to elevate the quality of care provided.
Continuous Commitment to Innovation
Dr. Emiliano Calvo, President of START Europe, echoed these sentiments, highlighting the importance of supplying innovative therapies to Spanish patients. He noted that the new unit is a testament to their dedication to advancing cancer treatment access across all communities in Spain.
About the Partnership and Its Goals
The freshly established START early phase unit in La Rioja aims to increase the variety of cancer clinical trials available, complementing existing facilities in Madrid and Barcelona. Both organizations are working collectively to improve patient outcomes and spearhead global cancer research efforts.
About The START Center for Cancer Research
The START Center, a leader in community oncology, contributes to the field by providing access to specialized preclinical and early-phase clinical trials of novel cancer treatments. With a record of over a thousand clinical trials, including 43 FDA or EMA-approved therapies, START showcases a powerful platform committed to transitioning clinical trials into actual treatments, offering hope to patients and families around the world. Find out more at STARTresearch.com.
About Fundación Rioja Salud
Founded in 2001, Fundación Rioja Salud has been at the forefront of biomedical research in La Rioja, hosting the Biomedical Research Center of La Rioja (CIBIR) since 2008. This foundation focuses on promoting health sciences and efficiently managing resources to advance research and knowledge in the region.
Frequently Asked Questions
What is the purpose of the partnership between START and Fundación Rioja Salud?
The partnership aims to enhance access to early-phase clinical trials for cancer patients in La Rioja, Spain, providing innovative treatment opportunities.
Where will the new START early phase unit be located?
The new unit will be co-located within San Pedro University Hospital, allowing for better access for cancer patients in northern Spain.
How many clinical trial sites does START currently operate?
START operates eight clinical trial sites globally, including established locations in Madrid and Barcelona.
What impact will this partnership have on the local community?
This collaboration will provide patients in the La Rioja region with access to cutting-edge cancer research and treatments that were previously unavailable.
Who will lead the new clinical trial site?
The site will be spearheaded by a team of experts from START in partnership with local healthcare professionals from Fundación Rioja Salud.
